
AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Zegna, you need to believe in its ability to grow as a global luxury house while managing execution risks in China and the Thom Browne wholesale reset. The appointment of a new Group CEO and fresh board representation is important for oversight, but the near term risk of higher SG&A and the shift toward direct to consumer remains largely unchanged by this news.
The most directly relevant move here is Zegna’s inclusion in the Russell 2000 Growth Defensive and Defensive indices, which may affect how diversified portfolios gain exposure to the stock. While this does not alter the company’s underlying earnings drivers, it can influence trading volumes and how the market frames Zegna’s balance between growth ambitions and a recurring dividend profile.
Yet investors should be aware that higher SG&A and expansion spending could still...
Read the full narrative on Ermenegildo Zegna (it's free!)
Ermenegildo Zegna's narrative projects €2.3 billion revenue and €158.6 million earnings by 2029.
Uncover how Ermenegildo Zegna's forecasts yield a $13.30 fair value, in line with its current price.
Simply Wall St Community members currently see Zegna’s fair value between US$8.57 and US$13.30, across 2 separate views. Set this against the ongoing risk that rising SG&A and store expansion could pressure margins if revenue growth slows, and you can see why it helps to compare several different viewpoints before deciding how the business might perform.
Explore 2 other fair value estimates on Ermenegildo Zegna - why the stock might be worth 37% less than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Opportunities like this don't last. These are today's most promising picks. Check them out now:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com